Creative Planning’s Aprea Therapeutics APRE Stock Holding History

Creative Planning’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25	Closed	-$105	–	2766
2023 Q3	$105	Buy	+25	New	+$91	﹤0.01%	2879

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Creative Planning's APRE Position: Q4 2023 in Review

Creative Planning sold out of Aprea Therapeutics (APRE) in Q4 2023, closing a stake of 25 shares — an estimated $105 sold.

Creative Planning first reported a position in APRE in Q3 2023 and held it in 1 quarter. The position peaked at $105 in Q3 2023. 20 funds tracked by Wall St. Rank hold APRE as of Q4 2023.

Creative Planning reported no remaining Aprea Therapeutics position as of Q4 2023 after selling out during the quarter.
Creative Planning sold 25 Aprea Therapeutics shares in Q4 2023, an estimated $105.
Creative Planning first reported a position in Aprea Therapeutics in Q3 2023 and held it in 1 quarter.
Creative Planning's Aprea Therapeutics position peaked at $105 in Q3 2023.
20 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2023.

Based on Creative Planning's 13F filing for Q4 2023, filed 14 Feb 2024.